Developing and Using Therapeutics for Emerging Infections
Identifieur interne : 000151 ( Istex/Curation ); précédent : 000150; suivant : 000152Developing and Using Therapeutics for Emerging Infections
Auteurs : Jeannine S. Mccune [États-Unis] ; Kellie S. Reynolds [États-Unis]Source :
- Clinical Pharmacology & Therapeutics [ 0009-9236 ] ; 2015-10.
Abstract
This issue of Clinical Pharmacology & Therapeutics focuses on emerging infections. The outbreaks of the vaccine‐preventable diseases (e.g., measles) and the emerging pathogens (e.g., Ebola) show us how small the world has become. These outbreaks also show the pressing need for effective public education and development of novel therapies. This issue covers various aspects of relevant therapeutic topics ranging from preclinical models, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial results, to education efforts in this area. Pharmacokinetic/dynamic modeling had an appreciable role in reducing the morbidity and mortality associated with human immunodeficiency virus and hepatitis C virus, recent emerging infections. However, these gains could be lessened by poor adherence to therapies, which has contributed to the development of multidrug‐resistant tuberculosis. We must not forget lessons from previous infections, or they may reemerge.
Url:
DOI: 10.1002/cpt.183
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000151
Links to Exploration step
ISTEX:06DBCF2DBEFEBB9445EA2CD450FEC12E9BE024E4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Developing and Using Therapeutics for Emerging Infections</title><author><name sortKey="Mccune, Jeannine S" sort="Mccune, Jeannine S" uniqKey="Mccune J" first="Jeannine S." last="Mccune">Jeannine S. Mccune</name><affiliation wicri:level="4"><mods:affiliation>Department of Pharmacy, University of Washington, Washington, USA, Seattle</mods:affiliation><orgName type="university">Université de Washington</orgName><country>États-Unis</country><placeName><settlement type="city">Seattle</settlement><region type="state">Washington (État)</region></placeName></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: jmccune@u.washington.edu</mods:affiliation><country wicri:rule="url">États-Unis</country></affiliation></author><author><name sortKey="Reynolds, Kellie S" sort="Reynolds, Kellie S" uniqKey="Reynolds K" first="Kellie S." last="Reynolds">Kellie S. Reynolds</name><affiliation wicri:level="1"><mods:affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Maryland, Silver Spring, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Maryland, Silver Spring</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:06DBCF2DBEFEBB9445EA2CD450FEC12E9BE024E4</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1002/cpt.183</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-ZJS4G057-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000151</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000151</idno><idno type="wicri:Area/Istex/Curation">000151</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Developing and Using Therapeutics for Emerging Infections</title><author><name sortKey="Mccune, Jeannine S" sort="Mccune, Jeannine S" uniqKey="Mccune J" first="Jeannine S." last="Mccune">Jeannine S. Mccune</name><affiliation wicri:level="4"><mods:affiliation>Department of Pharmacy, University of Washington, Washington, USA, Seattle</mods:affiliation><orgName type="university">Université de Washington</orgName><country>États-Unis</country><placeName><settlement type="city">Seattle</settlement><region type="state">Washington (État)</region></placeName></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: jmccune@u.washington.edu</mods:affiliation><country wicri:rule="url">États-Unis</country></affiliation></author><author><name sortKey="Reynolds, Kellie S" sort="Reynolds, Kellie S" uniqKey="Reynolds K" first="Kellie S." last="Reynolds">Kellie S. Reynolds</name><affiliation wicri:level="1"><mods:affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Maryland, Silver Spring, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Maryland, Silver Spring</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Clinical Pharmacology & Therapeutics</title><title level="j" type="alt">CLINICAL PHARMACOLOGY AND THERAPEUTICS</title><idno type="ISSN">0009-9236</idno><idno type="eISSN">1532-6535</idno><imprint><biblScope unit="vol">98</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="346">346</biblScope><biblScope unit="page" to="351">351</biblScope><biblScope unit="page-count">6</biblScope><date type="published" when="2015-10">2015-10</date></imprint><idno type="ISSN">0009-9236</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0009-9236</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">This issue of Clinical Pharmacology & Therapeutics focuses on emerging infections. The outbreaks of the vaccine‐preventable diseases (e.g., measles) and the emerging pathogens (e.g., Ebola) show us how small the world has become. These outbreaks also show the pressing need for effective public education and development of novel therapies. This issue covers various aspects of relevant therapeutic topics ranging from preclinical models, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial results, to education efforts in this area. Pharmacokinetic/dynamic modeling had an appreciable role in reducing the morbidity and mortality associated with human immunodeficiency virus and hepatitis C virus, recent emerging infections. However, these gains could be lessened by poor adherence to therapies, which has contributed to the development of multidrug‐resistant tuberculosis. We must not forget lessons from previous infections, or they may reemerge.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000151 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000151 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:06DBCF2DBEFEBB9445EA2CD450FEC12E9BE024E4
|texte= Developing and Using Therapeutics for Emerging Infections
}}
| This area was generated with Dilib version V0.6.33. |  |